SecBot SecBot
8-K ·Filed Nov 9, 2026

HRTX

HERON THERAPEUTICS, INC. /DE/
NEUTRAL
Impact 6/10
Horizonweeks Processed7d 19h ago SEC0001193125-26-452721
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The asset sale to CorMedix Therapeutics is the dominant event; monitor the proxy filing for the purchase price and stockholder vote timeline. The earnings release itself shows continued revenue decline in the core Oncology franchise, but the sale process makes standalone financial trends less relevant.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

HRTX drug pipeline →

APONVIE

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available since March 2023.
Next catalyst
None dated

What to watchAPONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.3706
T+0 close · Nov 9, 2026 · via day close
Latest settled
−23.29%
T+5 · $0.2843
Vs SPY
−21.59%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.3706entry
  2. T+1 · 7d ago +0.94%α +1.31% · $0.3741
  3. T+5 · 21h ago −23.29%α −21.59% · $0.2843
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Heron Therapeutics reported Q3 2026 net revenue of $35.3M, down 7.8% YoY from $38.2M, with the Oncology franchise declining 22.2% (CINVANTI -16.6%, SUSTOL sales ceased). The company announced a definitive asset purchase agreement under which CorMedix Therapeutics will acquire substantially all of Heron's assets, subject to stockholder approval.

Key Financial Metrics

EPS
−$0.03
est −$0.03 · 0.0%
Revenue
$35.3M
est $37.5M · -6.0% · -7.8% YoY
Rating
in line
Gross Margin
74.6%

Key Facts

  • Q3 2026 net revenue of $35.3M, down 7.8% from $38.2M in Q3 2025
  • Acute Care franchise revenue up 22.5% YoY to $15.1M
  • Oncology franchise revenue down 22.2% YoY to $20.1M
  • CINVANTI revenue down 16.6% YoY to $20.0M
  • SUSTOL commercial sales ceased on September 30, 2026
  • Cash, cash equivalents and short-term investments of $23.4M at quarter end
  • Entered into definitive asset purchase agreement with CorMedix Therapeutics for substantially all assets
  • Full-year 2026 financial guidance previously withdrawn in August 2026
  • GAAP net loss per share of $(0.03) vs $(0.10) in Q3 2025
  • Adjusted EBITDA of $3.7M vs $1.5M in Q3 2025

Financial Impact

Q3 revenue $35.3M, down 7.8% YoY; net loss $5.0M; cash burn continues with $23.4M in liquid assets

revenuenet losscash position

Segment Breakdown

SegmentRevenueGrowth
Acute Care$15.1M+22.5%
Oncology$20.1M-22.2%

Risk Factors

  • Asset sale requires stockholder approval and may not close
  • CINVANTI faces patent litigation risk and potential generic entry
  • Cash position of $23.4M may be insufficient if sale is delayed or fails
  • Stockholders' equity of only $4.9M indicates potential going concern risk absent the sale

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452721
Document: hrtx-20261109.htm0001193125-26-452721
Document: 0001193125-26-452721-index-headers.html0001193125-26-452721
Document: 0001193125-26-452721-index.html0001193125-26-452721
Document: 0001193125-26-452721.txt0001193125-26-452721
8-K Data (Synthetic)0001193125-26-452721

Track record

15 reports on HRTX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
  2. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  3. Nov 9, 20267d ago 8-K Neutral 6/10 Viewing Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  4. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  5. Nov 9, 20267d ago Press Release Mixed 7/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  6. Aug 10, 202614w ago 8-K Bearish 7/10 No price data
  7. Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
  8. Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
  9. Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
  10. May 11, 202627w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026